$BABA-W (09988.HK)$
Order

After the announcement from developer conference, $Zepp Health (ZEPP.US)$ has the potentials to be valued higher, coupled with the possible reversal due to expected sales improvement the rest of the year, ZEPP could surge to new all-time high to reflect all this optimism in the future.
In terms of popularity, Zepp Health is getting more and more attention from famous YouTubers and social media influencers who are bullish on it, and the popularity will gradually increase after their name and ticker change from Huami (HMI). Zepp Health officials have also begun to put more effort into investor relations, such as setting up IR accounts on Twitter and LinkedIn.
The product itself (such as Amazfit) has great user reviews. It is reported that it is now the number one in Brazil and number 4 globally. The large amount of health data collected due to its popularity and friendly pricing can potientially be analyzed by big data to fit their new health vision.
There should be a lot of room for growth in the future. For example, from the social media accounts it set up in multiple countries, I can see some of which are still in the initial stage and have a lot of room to grow, whereas some are already successful. Their ...

Although future is a bit uncertain due to US politics, and debt might be a concern, CEO and institutions like Blackrock and Vanguard have been adding.
A change of politic climate or company direction could improve fundamentals and return $The GEO Group Inc (GEO.US)$ to previous highs.
It is currently a heavily shorted value stock that happens to be recently turned into one of the WallStreetBets (WSB) favorites. A possible short squeeze would be tempting too.

If $DouYu (DOYU.US)$ gets acquired, it will go up quite a lot (recent examples: Pluralsight, Slack). If not, it is still a growth play currently at an attractive price due to being beaten down.

$Intellicheck (IDN.US)$
My Due-Diligence on Intellicheck:
- A cybersecurity company in the physical identity verification space with a very low market cap, with much growth possibility ahead
- Customers include US government and large companies such as banks
- US vaccination and economy recovery are beneficial to Intelicheck's per-user/per-scan charging model; the more people go out the better
- In the last earning call, they mentioned they will further grow by hiring sales people or related roles
- After changing the CEO around 2018, the company outlook became much better
Stock-wise:
- A small-cap growth stock that is less hot than mainstream stock. A goodie yet to be discovered. Get onboard earlier than others do.
- It is currently seriously beaten-down (from 15 USD to 7 USD) due to the sentiment again growth stock along with its less satisfactory quarterly earning report, but long-term outlook remains.
- The currently price around USD 7-8 has been consolidating for quite some time, and it seems that it doesn't want to fall further, now that an analyst raised it's target price to 12 at the time of writing. The stock offering last year was also around the price range of 7-8.
- Blackrock, The Vanguard Group keep on adding. Individual ...